BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//AssetMemo//Readout calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:TSN1611 readouts · AssetMemo
X-WR-CALDESC:Upcoming readouts of TSN1611\, from ClinicalTrials.gov estimat
 es.
REFRESH-INTERVAL;VALUE=DURATION:PT12H
X-PUBLISHED-TTL:PT12H
BEGIN:VEVENT
UID:NCT06385925-2780@assetmemo.bio
DTSTAMP:20261121T005619Z
DTSTART;VALUE=DATE:20271030
DTEND;VALUE=DATE:20271031
SUMMARY:TSN1611: Phase 1/2 readout est. (NCT06385925)
DESCRIPTION:TSN1611\, phase 1/2.\nStudy: A Study of TSN1611 Treating Patien
 ts With Advanced Solid Tumors Harboring KRAS G12D Mutation\nEstimated prim
 ary completion: 30 October 2027. This is a ClinicalTrials.gov estimate\, n
 ot a confirmed readout date\, and it can move.\nDrug page: https://assetme
 mo.bio/drug/tsn1611#upcoming-events\nRegistry record: https://clinicaltria
 ls.gov/study/NCT06385925
URL:https://assetmemo.bio/drug/tsn1611#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
END:VCALENDAR
